Skip to content
(Bloomberg) -- Gold and silver posted their biggest weekly losses since March, when the global onset of the coronavirus pandemic panicked markets.The dollar gained as concern over the outlook for global economic growth bolstered the appeal of the currency as a haven, sapping demand for gold. Fears are mounting that rising coronavirus cases, particularly in Europe, may lead to more national lockdowns, denting the outlook for recovery. Gold fell 4.6% this week, while silver slumped 15%.“Both have succumbed to belated long liquidation and pressure generated by the strength in the general dollar index, which is on track for its biggest weekly gain in almost six months,” Edward Meir, an analyst at ED&F Man Capital Markets in New York, said in a note.The rally in gold, often used as an inflation hedge, has also flagged as the dimming view of the recovery undercuts the outlook for a rise in consumer prices. A...
Maintenance experts share essential tools that ease the workload and keep the shop running smoothly. ...
The airline said it is retiring its Boeing 717-200 aircraft and the remainder of its 767-300ER aircraft from the fleet by December 2025. It is also retiring its CRJ-200 aircraft by December 2023, earlier than previously planned....
Teresa Jacobsen, a financial advisor at UBS Private Wealth Management, joined The Final Round to discuss her outlook for the market and what she thinks are the biggest headwinds facing the market right now....
Does AstraZeneca (AZN) still have a fighting chance in the COVID-19 vaccine race? Earlier this month, the healthcare giant paused the Phase 3 study of AZD1222, its experimental COVID-19 vaccine developed as part of a collaboration with the University of Oxford, after one of the participants developed an unexplained illness, a potential adverse effect. This effect was later described as transverse myelitis, a demyelinating condition.Even though the UK study has resumed, the U.S. study remains on hold. Against this backdrop, AZN released the protocol for the trial, demonstrating the “rigorous” criteria of the interim analysis, in SVB Leerink analyst Andrew Berens’ opinion.AZD1222's criteria for success is based on the FDA's Guidance for Industry regarding COVID-19 vaccine development, which asserts that an observed vaccine efficacy (VE) point estimate should be at least 50%, and that the lower bound of the confidence interval (CI) should be over 30%.AZN’s first interim analysis (IA) will...
Keeping your fleet on the road is more than just ensuring your trucks are ready to roll; trailers need love, too. ...
